Literature DB >> 30480492

Fluorine 18-FDG PET/CT and Diffusion-weighted MRI for Malignant versus Benign Pulmonary Lesions: A Meta-Analysis.

Adriano Basso Dias1, Matheus Zanon1, Stephan Altmayer1, Gabriel Sartori Pacini1, Natália Henz Concatto1, Guilherme Watte1, Anderson Garcez1, Tan-Lucien Mohammed1, Nupur Verma1, Tássia Medeiros1, Edson Marchiori1, Klaus Irion1, Bruno Hochhegger1.   

Abstract

Purpose To perform a meta-analysis of the literature to compare the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weighted (DW) MRI in the differentiation of malignant and benign pulmonary nodules and masses. Materials and Methods Published English-language studies on the diagnostic accuracy of PET/CT and/or DW MRI in the characterization of pulmonary lesions were searched in relevant databases through December 2017. The primary focus was on studies in which joint DW MRI and PET/CT were performed in the entire study population, to reduce interstudy heterogeneity. For DW MRI, lesion-to-spinal cord signal intensity ratio and apparent diffusion coefficient were evaluated; for PET/CT, maximum standard uptake value was evaluated. The pooled sensitivities, specificities, diagnostic odds ratios, and areas under the receiver operating characteristic curve (AUCs) for PET/CT and DW MRI were determined along with 95% confidence intervals (CIs). Results Thirty-seven studies met the inclusion criteria, with a total of 4224 participants and 4463 lesions (3090 malignant lesions [69.2%]). In the primary analysis of joint DW MRI and PET/CT studies (n = 6), DW MRI had a pooled sensitivity and specificity of 83% (95% CI: 75%, 89%) and 91% (95% CI: 80%, 96%), respectively, compared with 78% (95% CI: 70%, 84%) (P = .01 vs DW MRI) and 81% (95% CI: 72%, 88%) (P = .056 vs DW MRI) for PET/CT. DW MRI yielded an AUC of 0.93 (95% CI: 0.90, 0.95), versus 0.86 (95% CI: 0.83, 0.89) for PET/CT (P = .001). The diagnostic odds ratio of DW MRI (50 [95% CI: 19, 132]) was superior to that of PET/CT (15 [95% CI: 7, 32]) (P = .006). Conclusion The diagnostic performance of diffusion-weighted MRI is comparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT in the differentiation of malignant and benign pulmonary lesions. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Schiebler in this issue.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30480492     DOI: 10.1148/radiol.2018181159

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.

Authors:  Yuanyuan Jiang; Guozhu Hou; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2020-04       Impact factor: 1.698

Review 2.  Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses.

Authors:  Filippo Lococo; Barbara Muoio; Marco Chiappetta; Dania Nachira; Leonardo Petracca Ciavarella; Stefano Margaritora; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2020-04-25       Impact factor: 3.161

Review 3.  State-of-the-art MR Imaging for Thoracic Diseases.

Authors:  Yumi Tanaka; Yoshiharu Ohno; Satomu Hanamatsu; Yuki Obama; Takahiro Ueda; Hirotaka Ikeda; Akiyoshi Iwase; Takashi Fukuba; Hidekazu Hattori; Kazuhiro Murayama; Takeshi Yoshikawa; Daisuke Takenaka; Hisanobu Koyama; Hiroshi Toyama
Journal:  Magn Reson Med Sci       Date:  2021-04-29       Impact factor: 2.760

4.  The value of diffusion kurtosis imaging, diffusion weighted imaging and 18F-FDG PET for differentiating benign and malignant solitary pulmonary lesions and predicting pathological grading.

Authors:  Ziqiang Li; Yu Luo; Han Jiang; Nan Meng; Zhun Huang; Pengyang Feng; Ting Fang; Fangfang Fu; Xiaochen Li; Yan Bai; Wei Wei; Yang Yang; Jianmin Yuan; Jianjian Cheng; Meiyun Wang
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.